Superworth

Upstream Bio price to book ratio UPB

Market value divided by the book value of the company's net assets, since 2025.

Today, Oct 23, 2026
0.6×
Peer median
1.6×

Upstream Bio's price to book ratio is 0.6× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.6×0.6×4.4×
20254.2×0.7×4.2×

Against its peers

Companies in Drug Manufacturers - General nearest Upstream Bio's size, closest first, today.

CompanyPrice to book ratio
UPBUpstream Bio0.6×
NATRNatures Sunshine Products1.3×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
ATNMActinium Pharmaceuticals1.6×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
Peer median1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Upstream Bio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.